REGN
Regeneron Pharmaceuticals, Inc.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2026
- #206
- Final score
- 60.88
- Years on list
- 7
↘ Down 90 since 2020
Compare · Up to four Russell 1000 companies
Select two, three, or four Russell 1000 companies to compare their overall rank, year-by-year trajectory, and scores down to the category level.
Figure 01 · Side-by-side summary
Pharmaceuticals, Biotechnology & Life Sciences
↘ Down 90 since 2020
Pharmaceuticals, Biotechnology & Life Sciences
↗ Climbed 740 since 2022
Pharmaceuticals, Biotechnology & Life Sciences
↘ Down 69 since 2020
Figure 02 · Rank trajectory
Lower is better. The y-axis is inverted so a rising line means an improving rank. Missing years mean the company didn't make the top 100 that year.
Figure 03 · Pillar profile · 2026
Latest-year ESG pillar scores, 0–100. The shaded bar shows relative strength across the selected companies for each pillar.
| Pillar | REGN | OGN | AMGN |
|---|---|---|---|
| Climate Change | 71.1 | 67.8 | 64.9 |
| Employee Relations | 54.3 | 62.0 | 51.7 |
| Environment | 57.9 | 60.2 | 65.0 |
| Stakeholders & Society | 61.9 | 62.3 | 67.5 |
| Human Rights | 57.2 | 60.0 | 44.6 |
| Governance | 54.6 | 52.9 | 58.3 |
| Performance Rating | 71.7 | 57.7 | 69.8 |